PHASE 1B TRIAL OF MONALIZUMAB (NKG2A INHIBITOR) PLUS DURVALUMAB: SAFETY AND EFFICACY IN PATIENTS WITH METASTATIC OVARIAN, CERVICAL, AND MICROSATELLITE-STABLE ENDOMETRIAL CANCERS

被引：2
|
作者：
Banerjee, Susana [1 ,2 ]
Oaknin, Ana [3 ]
Sanchez-Simon, Inmaculada [4 ]
Salgado, Alfonso Cortes [5 ]
Patel, Sandip Pravin [6 ]
Oza, Amit [7 ]
Das, Mayukh [8 ]
Kourtesis, Panagiotis [8 ]
Ascierto, Maria Libera [8 ]
Diamond, Jennifer R. [9 ]
机构：
[1] Royal Marsden NHS Fdn Trust, London, England
[2] Inst Canc Res, London, England
[3] Hosp Valle De Hebron, Vall Dhebron Inst Oncol Vhio, Barcelona, Spain
[4] Hosp Univ Virgen, Granada, Spain
[5] Hosp Univ Ramon, Madrid, Spain
[6] Ucsd Moore Canc Ctr, La Jolla, CA USA
[7] Princess Margaret Canc Ctr, Toronto, ON, Canada
[8] Astrazeneca, Cambridge, England
[9] Univ Colorado, Ctr Canc, Boulder, CO 80309 USA
来源：
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER | 2020年 / 30卷
关键词：
D O I：
10.1136/ijgc-2020-ESGO.147
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
518
引用
收藏
页码：A86 / A87
页数：2
相关论文
共 50 条
  • [1] Translational endpoints in patients with metastatic microsatellite-stable colorectal cancer (MSS-CRC) treated with durvalumab plus monalizumab (anti-NKG2A)
    Diamond, J. R.
    Standifer, N.
    Ascierto, M. L.
    Morehouse, C.
    Ghadially, H.
    Canales, J. Rodriguez
    Rebelatto, M. C.
    Naidoo, J.
    Mazzarella, L.
    Patel, S.
    Flor Oncala, M. J.
    Alonso Gordoa, T.
    Wang, D.
    Song, X.
    Jones, D. C.
    Li, X.
    Marshall, S.
    Abdullah, S.
    Jure-Kunkel, M.
    Hellmann, M. D.
    ANNALS OF ONCOLOGY, 2018, 29
  • [2] Efficacy and safety of cobimetinib (cobi) and atezolizumab (atezo) in an expanded phase 1b study of microsatellite-stable (MSS) metastatic colorectal cancer (mCRC)
    Desai, J.
    Hong, Y. S.
    Kim, J. E.
    Kim, T. W.
    Han, S. W.
    Bang, Y-J.
    Chee, C. E.
    Heong, V. Y. M.
    Mcree, A.
    Chow, L. Q.
    Kwak, E. L.
    Infante, J. R.
    Wallin, J.
    Das Thakur, M.
    Mwawasi, G.
    Foster, P.
    Cha, E.
    Bendell, J. C.
    ANNALS OF ONCOLOGY, 2016, 27
  • [3] A phase 2 trial of trifluridine/tipiracil plus nivolumab in patients with heavily pretreated microsatellite-stable metastatic colorectal cancer
    Patel, Manish R.
    Falchook, Gerald S.
    Hamada, Kensuke
    Makris, Lukas
    Bendell, Johanna C.
    CANCER MEDICINE, 2021, 10 (04): : 1183 - 1190
  • [4] Phase 1b/2 trial of tucatinib plus trastuzumab plus /-chemotherapy or pembrolizumab in patients with metastatic HER2+GI cancers
    Shitara, Kohei
    Park, Haeseong
    Bekaii-Saab, Tanios
    Kim, Sunnie S.
    Kamath, Suneel
    Pishvaian, Michael J.
    Chen, Christopher
    Zhen, David B.
    Mayor, Joal
    Tan, Qianwen
    Strickler, John H.
    ANNALS OF ONCOLOGY, 2022, 33 : S502 - S502
  • [5] Safety and Efficacy of the Combination Lurbinectedin plus Doxorubicin from a Phase 1b Trial in Patients with Advanced/Metastatic Soft-Tissue Sarcoma
    Cote, Gregory M.
    Haddox, Candace L.
    Choy, Edwin
    Merriam, Priscilla A.
    Mazzola, Emanuele
    Venkataraman, Vinayak
    Alcindor, Thierry
    Wagner, Andrew J.
    Demetri, George D.
    George, Suzanne
    CLINICAL CANCER RESEARCH, 2024, 30 (13) : 2702 - 2708
  • [6] Binimetinib in combination with nivolumab or nivolumab and ipilimumab in patients with previously treated microsatellite-stable metastatic colorectal cancer with RAS mutations in an open-label phase 1b/2 study
    Elez, Elena
    Cubillo, Antonio
    Alfonso, Pilar Garcia
    Middleton, Mark R.
    Chau, Ian
    Alkuzweny, Baha
    Alcasid, Ann
    Zhang, Xiaosong
    Van Cutsem, Eric
    BMC CANCER, 2024, 24 (01)
  • [7] Phase 1b/2 study of binimetinib (BINI) in combination with nivolumab (NIVO) or NIVO plus ipilimumab (IPI) in patients (pts) with previously treated microsatellite-stable (MSS) metastatic colorectal cancer (mCRC) with RAS mutation.
    Bendell, Johanna C.
    Kopetz, Scott
    Middleton, Mark R.
    Eves, P. Taylor
    Bozon, Viviana
    Boyd, Adam P.
    Schellens, Jan H. M.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (04)
  • [8] Phase 1b/2 trial of ribociclib plus binimetinib in metastatic NRAS-mutant melanoma: Safety, efficacy, and recommended phase 2 dose (RP2D).
    Schuler, Martin H.
    Ascierto, Paolo A.
    de Vos, Filip Yves Francine Leon
    Postow, Michael Andrew
    Van Herpen, Carla M. L.
    Carlin, Matteo S.
    Sosman, Jeffrey A.
    Berking, Carola
    Long, Georgina V.
    Weise, Amy
    Gutzmer, Ralf
    Kaatz, Martin
    McArthur, Grant A.
    Schwartz, Gary
    Daud, Adil
    Maharry, Kati
    Yerramilli-Rao, Padmaja
    Zimmer, Lisa
    Bozon, Viviana
    Amaria, Rodabe Navroze
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [9] A phase Ib/ II trial to assess the safety and efficacy of CXD101 in combination with the PD-1 inhibitor nivolumab in patients with metastatic, previously-treated, microsatellite-stable (MSS) colorectal carcinoma (short title CAROSELL)
    Saunders, M. P.
    Graham, J.
    Cunningham, D.
    Plummer, R.
    Cook, S.
    Church, D.
    Kerr, R.
    La Thangue, N.
    Kerr, D. J.
    ANNALS OF ONCOLOGY, 2019, 30
  • [10] Safety and preliminary activity of naptumomab estafenatox (NAP) and durvalumab in patients with advanced or metastatic solid tumors: interim results from a phase 1b trial
    Geva, Ravit
    Stemmer, Salomon
    Perets, Ruth
    Maurice-Dror, Corinne
    Ben-Ami, Eitan
    Raphael, Ari
    Kumar, Sanjeev
    Lorber, Ilana
    Kedem, Tal Hetzroni
    Fields, Scott Z.
    Rozencweig, Marcel
    Golan, Talia
    CANCER RESEARCH, 2023, 83 (08)
12345